Launched in 2021, the Va-C-Nemus national prospective observational study involved 1,020 adults with a neuromuscular disease of genetic or autoimmune origin, 18% of whom were on corticosteroid and/or immunosuppressive therapy, 20% on respiratory assistance and 5% with cardiac involvement.
After one year of post-vaccination follow-up :
- the type and frequency of adverse events were similar to those in the general population, with less than a third of vaccine injections resulting in side-effects affecting daily activities, most without preventing them or leading to hospitalisation;
- side-effects were more frequent in cases of significant disability (a situation also at risk of severe forms of Covid-19) and with the anti-Covid 19 Moderna vaccine (but few patients were concerned);
- the risk of adverse events was not increased in the case of autoimmune disease or immune-mediated treatment.
The authors conclude that vaccination against Covid-19 proved safe in this study, the first of its scale and with such a wide range of neuromuscular diseases.
